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Abstract 
Background 
Catheter ablation has emerged as treatment for atrial fibrillation (AF). Health care-related 
variables have not been explored as predictors of first ablation outcome. Determining 
factors associated with arrhythmia recurrence may help select patients likely to benefit. The 
objective was to identify variables associated with recurrence following AF ablation.  
Methods 
Retrospective cohort design of 314 AF patients who had undergone first ablation. Follow-up 
visits occurred at 3, 6 and 12 months. Variables and the outcome of recurrence were 
modeled with Cox proportional hazards analysis. 
Results/Conclusions 
After mean follow-up of 239+/-125 days, 110/314 patients (35.0%) experienced recurrence. 
Adjusted Cox proportional hazards models demonstrated cardiomyopathy [HR (95% CI) = 
1.97 (1.13-3.41)] was associated with arrhythmia recurrence. Conversely, height per cm 
increase [HR (95% CI) = 0.96 (0.94-0.99)], and targeted ablation outside the pulmonary 
veins [HR (95% CI) = 0.531 (0.29-0.98)] were associated with hazard reduction. Wait time 
was not associated with recurrence.  
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Chapter 1  
1 Introduction 
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. It is 
characterized by disorganized electrical impulses in the upper chamber of the heart, 
resulting in an irregular and rapid heartbeat that can occur in episodes or last 
continuously. An electrocardiogram (ECG) or rhythm recording demonstrating AF 
lasting at least 30 seconds is considered an episode.1, 2, 3 
Overall, AF affects 1-2% of the population.4 Among adults aged 55 years or younger the 
prevalence of AF is less than 1%, though it rises with age to nearly 10% in adults over 
80. As the population ages, the absolute number of cases is expected to increase due 
to increased risk with age, combined with population aging. This presents a public 
health problem for planning future treatment capacity and resource utilization. AF 
increases the risk of stroke and is recognized as an independent predictor of morbidity 
and mortality in the setting of cardiovascular disease.5, 6, 3 
Although the etiology of AF is incompletely understood, AF is primarily initiated by 
triggers within the pulmonary veins (PVs).7, 8 Catheter ablation aims to electrically 
isolate the foci within the PV from the atria, thereby preventing the chaotic electrical 
signals from interrupting the normal conduction of the left atrium.9 It has emerged as a 
treatment modality for symptomatic patients who have not responded to medication.10, 11 
Acute procedural success is indicated by the electrical isolation of the PVs. Long-term 
results are heterogeneous and demonstrate a high rate of recurrence of atrial 
arrhythmias following the procedure. Although there have been advances in the 
catheter ablation technique, recurrence rates remain as high as 50% post-ablation in 
more chronic forms of the condition.12, 13 
PV reconnection, due to recovery of ablated areas or transient ablation related to poor 
catheter contact, has been postulated by several authors to be the cause of early 
recurrences.14, 15, 16, 17 However, there is uncertainty of the cause of recurrence and the 
progressive attrition in success over time, even after acute success.14, 15, 18 There has 
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been interest in identifying factors that contribute to arrhythmia recurrences after 
catheter ablation. Previous studies have assessed the impact of factors on the outcome 
of various catheter ablation techniques. However, contradictory results along with 
heterogeneous definitions of recurrence and blanking period lengths (i.e. the period of 
time between the procedure and when an arrhythmic episode is counted) across studies 
have not provided definitive conclusions. Variables that have been implicated as 
potential predictors of recurrence include: type of AF, increased left atrial diameter, 
decreased ejection fraction, hypertension, body size and left atrial fibrosis.19, 20 Cardiac 
risk factors including hypertension, diabetes, obesity and obstructive sleep apnea have 
been shown to independently increase the incidence of AF. 21-24 These risk factors are 
also associated with structural and electrical remodeling of the atria that leads to AF 
development and progression. 25-27  
The purpose of this study was to examine the associations of pre-procedural clinical, 
procedural and post-procedural variables with recurrence after successful ablation for 
AF. Using broad inclusion criteria, including comorbid conditions, this study will be 
representative of patients encountered in clinical practice. Randomized trials provide 
data on efficacy of treatment, but are performed under tightly controlled conditions on a 
highly select subgroup of potential subjects. Catheter ablation is not effective for all 
patients and high recurrence rates following ablation is a major challenge. Pre-
procedural screening of AF patients who are suitable for catheter ablation is critical for 
optimizing the success and safety of the procedure. Identifying factors that contribute to 
the recurrence of arrhythmia is of clinical importance to reduce healthcare costs and to 
avoid exposing patients to unnecessary procedures and related complications.  
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Chapter 2  
2 Literature Review 
Cardiac arrhythmia refers to an irregular heartbeat. Of the several types, atrial fibrillation 
(AF) is the most common cardiac arrhythmia. In AF patients, disorganized electrical 
impulses in the atria cause an irregular and often rapid heartbeat. AF affects 1-2% of 
the population, though the prevalence rises with age.1 The risk of stroke is increased in 
AF patients, and it is recognized as an independent predictor of morbidity and mortality 
in the setting of cardiovascular disease.2 Patients are often highly symptomatic, though 
symptoms affect patients differently due to varying episode duration, disease 
processes, and comorbid conditions.3 People with AF experience lower quality of life 
scores compared with the general population, healthy controls and other cardiovascular 
disease groups.4 
2.1 Classification of atrial fibrillation 
While there are several ways to categorize AF, there is agreement across several 
guidelines to classify AF as paroxysmal or persistent.3 Paroxysmal AF is defined as 
recurrent AF that resolves within 7 days, while persistent AF describes AF that 
continues beyond 7 days. Persistent AF can be further defined as longstanding 
persistent if the AF has continued beyond one year, or permanent if treatment has failed 
or has been discontinued.  
Although there is agreement in the categorization of AF, previous studies have 
employed various criteria to define type of AF. Furthermore, persistent and paroxysmal 
AF are not mutually exclusive. The transient and often variable nature of AF poses limits 
to categorization based on patterns. Patients can experience episodes consistent with 
both persistent and paroxysmal AF categories. It has been recommended to categorize 
the patient based on the dominant AF pattern.3 However, there are not any 
investigations that specifically address the intra- or inter- observer reliability of the 
existing classifications. This is of interest because associations of type of AF and other 
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variables may be inconsistent in the current published literature due to variations in 
classification.   
AF often occurs in patients with heart conditions, including heart disease, hypertension, 
lung disease, or those who have undergone cardiac surgery. However, 10% of patients 
with AF do not have an associated cardiac condition and were previously classified as 
“lone AF,” while patients with concomitant heart conditions were distinguished as 
“secondary AF.” The current recommendations advise against using this definition so 
treatment is not influenced.3 Along with cardiac conditions, familial, genetic, behavioural 
factors and biochemical markers have been implicated as risk factors for AF.  
2.2 Healthcare burden 
Healthcare costs associated with AF have increased and are expected to continue 
rising as the population ages.5 Although there is a paucity of Canadian AF cost and 
healthcare burden data, O’Reilly and colleagues published a national database study 
with data from fiscal year 2007/2008.6 The authors estimated 22,823 (68 per 100,000 
population) hospital admissions and 68,066 (174 per 100,000 population) emergency 
department visits nationally were directly attributable to AF. The average length of stay 
was 5.7 days, with an average admission cost of $6718. Nationally, the estimated total 
cost for the fiscal year was $223 million. Conditions related to previously diagnosed AF 
accounted for significantly higher costs and longer hospital admissions. The additional 
cost for AF as a comorbidity was $558 million. However, the province of Quebec (23% 
of the nation’s population) does not contribute admissions data to the national database 
analyzed in this study, and Ontario is the only province to contribute complete 
emergency department and single day admissions data. The estimates are likely 
underestimated because the results were extrapolated to provinces with missing data 
solely on age and sex demographic data, without taking into account the varying risk 
profiles of Canadians across the country. In spite of problems with data quality, these 
estimates highlight the significant healthcare resource utilization and cost burden of AF.  
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2.3 Procedural and healthcare related factors 
2.3.1 Medication 
Management of AF has traditionally been medication-based, intended to either control 
heart rate or maintain sinus rhythm.7 A rate control and anticoagulation strategy allows 
AF to recur or persist, but controls the ventricular rate during episodes to control 
symptoms and reduce the risk of stroke. Rhythm control attempts to restore and 
maintain sinus rhythm, though it can be very difficult to achieve in some patients using 
medications alone. There has been a lack of compelling evidence demonstrating rhythm 
control offers a survival advantage over rate-control strategies.7 
2.3.2 Catheter ablation 
Catheter ablation aims to electrically isolate the tissue where AF most frequently starts 
thereby preventing chaotic electrical signals from disturbing the normal conduction 
patterns.10 Radiofrequency energy is delivered from the catheter, creating many small 
lesions to block the electrical conduction contributing to AF. Pulmonary vein isolation 
(PVI) is the most common ablation technique. The procedural end point is electrical 
isolation of the left and right pairs of pulmonary veins (PVs) from the left atrium.11, 3  
Catheter ablation is a curative treatment for AF. Due to the infrequent but potentially 
serious risk involved, it is currently reserved for symptomatic paroxysmal AF patients 
who have not responded to at least one anti-arrhythmic medication.3 Randomized, 
multicenter trials have demonstrated that while both medication and ablation therapies 
reduced AF burden, ablation results were markedly better.8 Importantly, patients who 
underwent catheter ablation had higher quality of life scores and wellness scores and 
better exercise capacity than the patients on anti-arrhythmic drugs (AADs). Wazni and 
colleagues9 trialled ablation as a first-line treatment approach instead of waiting for 
patients to become unresponsive to AADs and demonstrated comparable success 
rates, establishing that in some patients AADs are not required. These studies all 
demonstrated that adapting AF treatment strategies and considering ablation as a first 
or second line therapy is more effective than multiple AAD treatments. However, the 
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most recent guidelines for the management of AF continue to recommend ablation in 
paroxysmal AF patients only after they have failed at least one AAD, and recommend 
more limited use in persistent AF patients.3 
There have been advances in the catheter ablation technique since its inception, but 
arrhythmia recurrence rates remain as high as 50% in persistent AF and post-ablation 
outcomes have not improved proportionately.12, 13 Although the procedure has become 
more uniform across different health care centers, variations in end-points, definitions of 
recurrence and ultimately differences in procedural success persist as the search for 
improved outcomes continues. Direct comparisons across previous studies is difficult, 
and complicating matters, some studies include only off-AAD sinus rhythm as the 
definition of success, while others include patients maintaining sinus rhythm on AADs 
as successes. Clinical trials are often limited to a select group of patients and are not 
representative of patients seen in clinical practice.  
2.3.3 Technique  
Often the type of AF helps inform operators whether additional ablation lesions will likely 
be required and may help predict the response to the therapy. Isolation of the 
pulmonary veins alone is often sufficient to treat patients with paroxysmal AF, but 
suboptimal results are observed in patients with persistent AF.14 Initial reports of 
persistent AF ablation demonstrated that PVI achieved arrhythmic resolution in 85% of 
paroxysmal AF patients compared to just 29% for persistent AF.11  
Persistent AF requires elimination of initiating sites in the pulmonary veins, but also may 
entail ablation of sites in the left atrium that can cause AF to persist. In theory, AF is 
less likely to persist once modification to the atrial substrate, specifically ‘rotor’ sites, has 
occurred. Improvements in identifying these points with ablation techniques have 
resulted in enhanced success in persistent AF patients in some studies. In a small study 
of 74 patients with paroxysmal AF, Jais et al found that additional targeted ablation lines 
only in patients where AF or atrial flutter was inducible helped reach a success rate of 
91%.15 The endpoint was non-inducibility of AF and atrial flutter and additional lesions 
were performed until foci were uninducible. By tailoring the procedure to target foci in 
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each patient, unnecessary lesions were avoided. In contrast, a study of 144 paroxysmal 
and persistent patients by Leong-Sit and colleagues found that aggressive stimulation 
and subsequent ablation of induced arrhythmias was limited in predicting freedom from 
arrhythmia after ablation.16 The authors found persistent AF was independently 
associated with recurrence (OR = 2.43) along with left atrial size (OR = 2.18).  
Persistent AF episodes result in changes from electrical foci propagating AF to 
underlying electro-anatomical changes that further perpetuates AF. Willems et al17 
compared PVI alone to PVI and substrate modification of the left atrium in persistent AF 
patients. After a mean follow up time of 487 days, only 20% of persistent AF patients 
were free of recurrence, while 69% of patients who underwent the hybrid procedure 
remained in sinus rhythm. Gaita and colleagues18 expanded these results to both 
paroxysmal and persistent patients and demonstrated the addition of linear lesions to 
PVI provides greater long-term success free from AF in both patient groups compared 
to PVI alone. In the paroxysmal AF group, there was not a significant difference in 
ablation strategy outcomes at 1 year follow-up, but the hybrid approach was significantly 
superior over long-term follow-up. This reinforces the notion that as AF duration 
increases so does substrate degradation and without intervention the arrhythmia 
progresses towards atrial changes that further perpetuates AF.19 On-treatment analysis 
of the Conventional ablation for AF with or without focal impulse and rotar modulation 
(CONFIRM) trial suggested fewer AF ablation failures when all sources are eliminated, 
with a graded increase in recurrence of arrhythmia with more sources missed.20 
In a sub-study of the CONFIRM trial, Baykaner and colleagues21 identified stable AF 
sources in 97.1% of patients. Higher counts of concurrent stable sources per patient 
were associated with obstructive sleep apnea, enlarged left atrial (LA) diameter, obesity, 
and heart failure. Concurrent sources of AF observed in this study indicate a tailored 
approach is necessary. Indeed, single procedure freedom from recurrence was 90% in 
patients receiving targeted ablation compared to 44% for conventional ablation only.  
12 
 
Complex fractionated atrial electrograms (CFAEs) have been investigated as a target of 
ablation in persistent AF patients.22 CFAEs are often slow “rotors” of continuous 
electrical conduction and representative of phenomena that facilitate AF. Andrade et al23 
found CFAE ablation alone resulted in high rates of early and late recurrence, with early 
recurrence also predicting late recurrence. However, a hybrid CFAE plus PVI procedure 
increased long term success without an increase in early recurrence. In contrast to the 
traditional approach of substrate modification, however, this international, randomized 
trial of ablation failed to detect any outcome advantage to substrate modification (roof 
line or mitral annulus line) over simple isolation of the pulmonary veins.23 This has 
recently led to significant debate in the arrhythmia community regarding whether a 
simple pulmonary vein isolation is sufficient as initial approach to persistent AF, or 
whether some specific patient groups may be more amenable to some form of substrate 
modification. 
Elayi et al24 randomized longstanding persistent AF patients to 3 groups consisting of 2 
different approaches to ablation and PV ablation plus targeting CFAEs. After one 
procedure, 61% of patients with the combination ablation approach of targeted CFAEs 
and ablation were in sinus rhythm without antiarrhythmic medications, while only 11% 
and 40% of those in the first two groups maintained sinus rhythm over a mean follow-up 
period of 16.4 months. However, the selective nature of patients enrolled in clinical trials 
may limit the generalizability of these studies. 
While therapeutic strategies for targeting CFAEs remain to be exploited, new algorithms 
for mapping CFAEs are continually being developed but have not yet been used 
clinically.25 Ablation procedures continue to advance, but the recurrence rate and 
predictors of recurrence remain inconsistent. Within randomized trials, one year 
recurrence rates following ablation for AF have ranged from 23-44%.8,9,26 Evidence from 
clinical trials suggests that although persistent AF patients have higher rates of 
arrhythmia recurrence post-ablation, both paroxysmal and persistent AF patients may 
benefit from additional targeted ablation lesions. 
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2.3.4 Operator experience 
Catheter ablation is a complex procedure and operator experience plays a key role in 
outcomes including complications. One study demonstrated a temporal trend in fewer 
complications with advanced operator experience, even in the absence of change to the 
ablation technique.27 Fewer complications occurred over time, with a senior operators 
reporting fewer complications and shorter procedural durations than junior operators, 
although the difference was not statistically significant. Broader patient inclusion has 
been observed over time, along with advances in ablation technique, and improvements 
in operator skill with more ablations.28 
2.3.5 Wait time 
Catheter ablation requires specialized skill and is still performed in relatively few 
centers. Time waited for catheter ablation has not been explored, likely because wait 
times are not currently a widespread issue in the United States. However, long waiting 
lists for ablation, resulting in treatment delays, may be problematic in countries with a 
single payer healthcare system. In 2006, the Canadian Cardiovascular Society Access 
to Care Working Group and the Canadian Heart Rhythm Society published medically 
acceptable wait times for outpatient assessment and non-invasive investigations of a 
patient with AF of no longer than four to 12 weeks, depending on the urgency of the 
need for consultation, and no longer than 12 weeks for catheter ablation procedures in 
the absence of structural abnormalities.29 Gillis and colleagues30 examined wait times 
for AF patients to be assessed by a cardiologist or electrophysiologist in the Calgary 
Health Region (Alberta, Canada). The mean wait time was 80+/-55 days from referral 
date to an in-personal specialist visit. It is currently unknown how long Canadians wait 
for ablation procedures subsequent to the initial consultation or whether wait times 
impact procedural success. 
2.4 Patient factors 
Catheter ablation is constantly evolving, but no single approach to ablation has 
garnered full success, even in the short term. Most recurrences are presumed to result 
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from electrical reconnection at the pulmonary veins, though there is little evidence to 
suggest how or why it occurs.   
2.4.1 Body size and left atrial size 
Several factors interact to cause AF and there is evidence to suggest the same factors 
are implicated in the recurrence of AF. Incident AF is associated with advanced age, 
male sex, and conditions including hypertension.31 More recently, additional conditions 
have been implicated in the initiation of incident AF, including obesity and sleep 
apnea.32 Several large cohort studies have reported a positive linear association with 
BMI and risk of AF.33-35 Furthermore, a meta-analysis of 5 population-based cohort 
studies including over 78,000 individuals observed a direct proportional increase in AF 
risk with increased BMI and found that obese individuals have a 49% higher risk of 
developing AF compared to their non-obese counterparts.36 However, the authors failed 
to find an association between an increased AF risk in obese vs. non-obese individuals 
who had previously undergone cardiac surgery. Following catheter ablation, freedom 
from arrhythmia recurrence is not uniform and is reduced in patients with risk factors 
involved in AF initiation.37, 38 However these results have not been consistent and it is 
unclear why some patients are more difficult to treat.  
Obesity is a risk factor for many conditions linked to AF including hypertension, sleep 
apnea, and enlarged left atrium diameter.36 It is unclear whether obesity itself is 
associated with AF because it is associated with many conditions implicated in the 
development of AF. Left atrial (LA) diameter is also strongly associated with height, and 
a larger left atrium has been linked to a higher risk of AF.39 A larger LA diameter for 
height may be indicative of obesity-related processes.40 LA diameter also tends to 
increase with age, though it may be more reflective of the pathophysiological changes 
that accompany advanced age, rather than chronologic age itself.41 VASAN et al39 
found a graded increase in hazard of AF development from the 95th to 99th percentiles 
of LA diameter for height. There was a 4.4-fold hazard for subjects above the 99th 
percentile of LA diameter vs. those in the 95th percentile or less. Similarly, Wang et al33 
found that after risk adjustment, a 4% increase in risk of incident AF for each 1 unit BMI 
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increase observed in both sexes was eliminated after adjustment for LA size. Enlarged 
LA diameter is associated with many patient characteristics and disease processes.  
Baykaner and colleagues21 found remote sources of ectopic activity in the right atrium of 
obese patients, a location not typically targeted in ablation for AF. It is currently 
unknown if this area of activation is common in obese patients, but it may help explain 
the high rates of recurrence in this population. 
2.4.2 Age  
The prevalence of AF increases with age, and age-related changes in the heart are 
common.41 Elderly patients are often excluded from clinical trials for AF ablation so it 
remains uncertain whether age is associated with the outcome of catheter ablation. An 
observational study found no difference in complication rates and AF control in patients 
grouped by age following catheter ablation (<65 years of age, age 65 to 74 years, age 
75 year or older).42 However, the outcome measure, AF control, included 
pharmacological measures, and reported lower recurrence rates. In this study, older 
patients were more likely to be female, and have structural heart disease or 
hypertension.  
2.4.3 Cardiac-related conditions 
Vaziri et al40 found elevated blood pressure was significantly associated with increased 
left atrial size, even after adjusting for age and BMI. In this sample, BMI was the most 
powerful determinant of LA size. Hypertension creates an overload of volume and/or 
pressure, altering the atrial substrate and encouraging AF propagation.  
Hypertrophy cardiomyopathy (HCM), a common heritable heart disease that can lead to 
heart failure, has presented a challenge for catheter ablation success for AF. Bassiouny 
et al43 found a 39% success rate of single catheter ablation for cardiomyopathy patients. 
However, symptomatic improvements were observed. Persistent AF predicted higher 
recurrence rates. Di Donna and colleagues9 found similar low success rates in 
cardiomyopathy patients undergoing initial catheter ablation for AF. After subsequent re-
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ablation, the overall success was similar to that of patients without HCM after first 
ablation.  
AF and heart failure share many of the same risk factors. Bertgalia et al45 found that 
structural heart disease was a predictor of early recurrence. Structural remodelling from 
heart failure results in atrial dilatation and widespread fibrosis, both of which perpetuate 
AF. The presence of structural heart disease precludes left atrial remodeling and 
enlargement, which are likely involved in the complex mechanisms resulting in early 
electrical reconnection of the PVs. 
2.4.4 Obstructive sleep apnea 
Obstructive sleep apnea (OSA) is associated with significant morbidity and mortality. It 
is associated with AF, obesity, older age and heart conditions. In multivariable analysis, 
Matiello and colleagues46 found that severe obstructive sleep apnea (OSA) and 
enlarged LA diameter were independent risk factors for recurrence. However, significant 
differences were observed between OSA and non-OSA patients at baseline that 
suggests OSA patients have more advanced AF. The association between OSA and 
recurrence may be more complicated. Patients in the OSA group had high incidence of 
persistent AF, and higher BMI, along with higher rates of hypertension and structural 
heart disease. In this analysis, the treatment of OSA with continuous positive airway 
pressure (CPAP) did not affect the results. Conversely, Fein and colleagues47 compared 
OSA CPAP-users to OSA non-users and non-OSA patients and found similar baseline 
characteristics. They found that OSA patients not treated with CPAP had more than a 
two-fold higher risk of recurrence after PVI. It is uncertain whether the acute effects of 
apnea events or the related structural changes predispose OSA patients to AF, and it 
may have important therapeutic implications. 
2.5 Variations in existing literature  
In a meta-analysis, the single factor that demonstrated a potential link to recurrence 
after ablation was type of AF.48 This association was only observed in univariable 
analysis, and the disappeared when adjusted in multivariable analysis.  
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There is significant heterogeneity between studies investigating predictors of 
recurrence. Individual studies have found a variety of different associations between 
patient characteristics and recurrence, but the results are often not reproducible.   
2.5.1 Type of atrial fibrillation 
AF leads to both electrical and anatomical remodeling of the atrium which may facilitate 
the persistence of AF.49 The degree and longevity of damage caused by atrial 
remodeling will consequently be reflective of the changes associated with more 
persistent AF. Wijffels and colleagues50 demonstrated that induced AF will self-
perpetuate over time – “AF begets AF”. Over time, paroxysmal AF episodes can 
become longer-lasting and more difficult to treat, resulting in the progression from 
paroxysmal to persistent AF. Kerr et al19 found that 25% of paroxysmal AF cases 
progressed to permanent AF within 5 years, accompanied by a significant increase in 
symptoms. This presents a challenge for the clinical categorization of AF. Paroxysmal 
AF describes short episodes less than one week in duration without the need for 
intervention. However, some longer lasting episodes may demonstrate the progression 
from paroxysmal to persistent AF, but complicate the clinical categorization. There is not 
consistent agreement with how paroxysmal and persistent AF should be defined, which 
limits the comparability between studies. Additionally, “permanent AF” patients have 
been included in studies even though they would actually be classified as persistent.3 
Permanent implies that treatment has ceased, but performing ablation on these patients 
calls into question the permanent AF category.  
Indeed, some studies have found associations between AF type and recurrence of AF 
after catheter ablation, while others have not. Similarly, some studies have shown 
statistically significant differences in clinical and procedural variables in persistent and 
paroxysmal patient groups, while others have failed to find differences. This may be 
indicative of classification deviation. 
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2.5.2 Recurrence 
Several studies have postulated that early recurrences are a result of incomplete 
ablation and residual PV conduction reinitiates AF.51-53  A “blanking” period of 3 months 
following ablation is often used and has been recommended in international and 
national guidelines.3 This constitutes a time where AF may recur but should not be 
considered a procedural failure unless it persists beyond this period, due to the 
assumption that post-ablation AF is more likely related to inflammation from the 
procedure itself as opposed to recurrent vein conduction. However, there is limited 
evidence for the blanking period and it may discount the importance of recurrences 
during this time.  
The ablation procedure itself induces swelling that may cause transient conduction 
block during the procedure, only to resolve within days or weeks. Despite the ‘acutely 
successful’ procedure, lasting conduction block may not be achieved in some patients. 
Indeed, Bertaglia and colleagues45 found a 46% relapse rate of atrial arrhythmias during 
the first three months of follow-up. Furthermore, the incidence of early recurrence is at a 
maximum shortly after the procedure which is perhaps indicative of acute thermal injury 
and subsequent recovery.54 Joshi and colleagues54 identified early recurrences in 65% 
of the patients with continuous monitoring. An earlier report of Oral et al11 suggests only 
31% of patients with early recurrence will have long-term freedom of AF. 
Additionally, several studies have found associations between early recurrences within 
the blanking period and late recurrences.23 Different blanking periods have been used 
which likely influence the reported recurrence rates in both clinical trials and 
observational studies. Moreover, some investigators prescribe patients AADs during the 
blanking period, while others do not, resulting in even greater variation.  
In the CONFIRM sub-study of targeted ablation, Baykaner et al21 calculated recurrence 
rates using two definitions of recurrence: AF only compared to AF and atrial 
tachycardias. Though not statistically significant, differences in proportions of 
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recurrence were observed, depending on which definition was employed. Higher 
recurrence rates were observed when the failure definition was widened. Predictors of 
recurrence may prove to be different even within the same study depending on the 
definition of recurrence. 
Most studies have only examined outcomes within 1 year, though long-term data 
available suggest a continued risk of recurrence beyond one year. After acute 
procedural success, there is uncertainty of the “cause” of later recurrence and continued 
attrition observed with time. 
2.6 Procedural risks 
Although the risk of any complication has decreased as the procedure has advanced 
over time, no procedure is without risk. Currently, the risk of complication is 2-3%, with 
vascular access complications being the most common, while fatal complications are 
rare.3,28 Prior to and following ablation, patients are prescribed blood thinners to reduce 
the risk of blot clots forming within the left atrium due to ablation, which can result in 
heart attack or stroke. Stroke is a risk of AF itself, but the procedural risks must be 
weighed against the potential benefits. Prevention of complications is based on 
antithrombotic therapy and adequate treatment of concomitant cardiac disease. 
2.6.1 Stroke 
The risk of stroke is not homogenous in AF patients. Well-established risk factors have 
been used to formulate scoring systems to evaluate the stratified risk of stroke.55 The 
most widely used scoring system in AF research is the Cardiac Failure, Hypertension, 
Age >= 75, Diabetes, Stroke (CHADS2) score.56 Each of the risk factors is worth one 
point, except stroke or TIA which counts for two in a validating scoring system that 
correlates CHADS2 score with stroke risk.  
2.7 Conclusions 
There has been interest in identifying factors that may contribute to AF recurrence after 
catheter ablation. Previous studies have assessed the impact of factors on the outcome 
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of various catheter ablation techniques. However, contradictory results along with 
heterogeneous definitions of recurrence and blanking periods across studies have 
prevented definitive conclusions. Variables that have been implicated as potential 
predictors of procedural failure include type of AF, increased left atrial diameter, 
hypertension, age, and obesity. These factors are also implicated in the development of 
AF.  
Catheter ablation is not necessarily effective for all patients and high recurrence rates 
following ablation is a major challenge. Wait times for ablation have not been 
characterized and it is unknown whether time waited affects outcome. Pre-procedural 
screening of AF patients who are suitable for catheter ablation is critical for optimizing 
the success and safety of the procedure. Identifying factors that contribute to the 
recurrence of arrhythmia is of clinical importance to reduce healthcare costs and avoid 
exposing patients to unnecessary procedures and related complications.  
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Chapter 3  
3 Objectives 
Recurrence of atrial arrhythmias following catheter ablation remains problematic. 
Understanding the relationship between the patient characteristics, procedural, health 
care factors and recurrence may facilitate the identification of patients most and least 
likely to benefit from the procedure.   
The identification of key factors related to procedural failure may lower health care costs 
and avoid exposing patients to unnecessary procedures and related complications 
when minimal benefit is expected. The proposed study will provide insight into 
recurrence of arrhythmias following catheter ablation for atrial fibrillation in the Canadian 
context. 
The literature reveals heterogeneity in both direction and strength of association of 
predictive factors. We aimed to contribute to the understanding of recurrence of 
arrhythmia following catheter ablation of AF, with the following specific objectives: 
 
3.1 Research objective 1 
- To determine the outcome of catheter ablation on AF recurrence after catheter 
ablation at University Hospital, London, Canada 
- To assess the relationships between patient, procedural, and healthcare-related 
variables and the outcome of catheter ablation among AF patients undergoing 
initial catheter ablation 
3.2 Research objective 2 
- To compare the differences in baseline clinical and procedural characteristics 
and outcomes in paroxysmal vs. persistent AF patients undergoing initial catheter 
ablation  
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3.3 Other objectives 
- To review the peer-reviewed literature on recurrence of atrial arrhythmias in AF 
patients who have undergone catheter ablation, and compare our findings to 
other published results 
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Chapter 4  
4 Methods 
The methods for the current study are detailed in Chapter 5 as a section of the 
integrated article. To avoid duplication, below is a summary of the methodology along 
with additional information beyond the scope of the article. 
4.1 Research Design 
Data from an atrial fibrillation clinical database started in 2009 at Arrhythmia Service at 
University Hospital (London Health Sciences Centre) was used for this retrospective 
cohort study. Data was recorded from AF patients enrolled prior to catheter ablation and 
include patient, treatment, and follow-up factors. Patients were routinely followed up at 
3, 6 and 12 months post-ablation. All patients provided both informed consent for the 
procedure and permission for their data to be used in research studies. This study was 
approved by Western University Ethics Board for Health Sciences Research and LHSC 
Lawson approval (see Appendix 1). Prior REB approval 17108E (ROMEO #7075) was 
obtained for the creation of the database.  
4.2 Study population 
All patients from the database were included in the current study who had either 
symptomatic paroxysmal or persistent AF, had failed at least one anti-arrhythmic drug 
(AAD), and had not previously had a cardiac ablation procedure.1 Patients were not 
excluded on the basis of comorbid conditions, including underlying cardiovascular 
disorders or structural abnormalities (hypertension, coronary artery disease and 
cardiomyopathies). Patients were enrolled with procedures and follow-up between 2009 
and 2013 who had at least one follow-up visit.  
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4.3 Procedure 
All patients underwent a standard pulmonary vein isolation ablation under either general 
anesthetic or deep sedation. Using an electroanatomic mapping system, a 3D anatomic 
map of the left atrium was created to guide the procedure. Circumferential ablation 
lesions were made to encircle both left and right pulmonary vein ostia. If the patient had 
persistent AF, was in AF during the procedure and it did not terminate during ablation, 
supplementary ablation lines were created as necessary by the operator to achieve 
electrical conduction block across the LA roof and/or in the mitral isthmus, at the 
discretion of the physician. Ablation effect was confirmed by reduction of local 
electrogram amplitude by at least 50% and at least 60 seconds of ablation at each 
ablation site.  
4.4 Follow up 
Patients were followed on an ambulatory basis with clinical examinations at 
approximately 3, 6 and 12 months following the procedure. Clinic visits included ECG or 
24-hour Holter monitor, symptom review and patient history updates. Additional clinical 
visits were scheduled if indicated by symptoms.  
Arrhythmia-free survival was measured in days from the procedure until recurrence was 
documented or until censoring occurred. Data were censored at the last known follow-
up visit in the outpatient clinic or at 400 days (one year with one month of run-out). 
4.5 Variables investigated  
Data was collected from patients at their first visit to the outpatient clinic prior to ablation 
and data was later verified by the research nurse against medical records.  
4.5.1 Baseline sociodemographic and clinical data 
Biological sex was recorded at the first arrhythmia clinic encounter prior to ablation. 
Patient age was derived as a whole number, in years, from the time between date of 
birth and procedure date. Type of AF was categorized as Paroxysmal AF (primarily 
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episodes that resolve within 7 days) and persistent AF (episodes continuing beyond 7 
days).1 Left atrial diameter (LAD) was measured (in mm) from echocardiography prior to 
ablation. Body mass index (BMI) was calculated as kg/m2 from height (in cm) and 
weight (in kg) measurements at baseline. BMI was also analyzed as a categorical 
variable according to World Health Organization criteria: normal weight (BMI 18.5-
25kg/m2), overweight (BMI 25-30 kg/m2) and obese (BMI greater than 30kg/m2).3  
A measure of stroke risk, the CHADS2 score, was calculated for each patient, with one 
point for each of: Cardiac Failure, Hypertension, Age >= 75, Diabetes, and two points 
for previous stroke or transient ischemic attack (TIA) for a theoretical range of 0 to 6. 
Because a small proportion of patients had higher scores, CHADS2 scores were 
dichotomized as ≤ 1 (few risk factors; low risk of stroke) vs. ≥2 (more risk factors; higher 
risk of stroke).  
Patients were asked about history of cormorbid conditions including hypertension, 
diabetes, prior stroke/TIA, coronary disease, cardiomyopathy, depression, alcohol use, 
sleep apnea and heart failure. Existing and previous health conditions were assigned as 
binary variables with yes or no responses. 
4.5.2 Procedure-related variables 
Procedure duration and fluoroscopy duration were each recorded during the procedure, 
in minutes. Additional areas for ablation were targeted if the patient was in AF during 
ablation and remained in AF after the initial pulmonary vein isolation, at the discretion of 
the treating physician. Specific targets include: LA roof line, CFAE, mitral isthmus line, 
tricuspid isthmus line. Cardioversion following the procedure was performed if patients 
remained in AF after substrate modification.  
4.5.3 Healthcare-related 
Wait time was calculated as months from the date the procedure was ordered to the 
scheduled procedure date, according the clinical records.  
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Anti-arrhythmia medications were discontinued prior to surgery. Because all patients 
had failed at least one medication, specific medications were not analyzed in this study.  
4.6 Outcome 
4.6.1 Recurrence  
Recurrence was defined as at least one episode of documented atrial arrhythmia lasting 
more than 30 seconds at any time within the study period after one procedure. No 
blanking period was used in this study as there has been conflicting evidence of its 
validity. Therefore, arrhythmias were classified as recurrent even within the first few 
months of the procedure and patients who experienced recurrence were offered a 
second ablation.  
4.6.2 Time to recurrence 
Arrhythmia-free survival time was measured in days from procedure until recurrence 
was documented, or until censoring occurred. Patients were censored at their last visit 
to the outpatient clinic or at 400 days (one year with one month of run-out). 
4.7 Statistical Analysis 
All statistical analyses were performed in SAS v. 9.3. 
Continuous variables were expressed as mean ± SD and categorical variables were 
expressed as counts and percentages. To compare paroxysmal and persistent AF 
patients at baseline, Student’s t-test or the Wilcoxon rank-sum test were used to 
analyze continuous variables, as appropriate. Categorical variables were analyzed 
using the chi-squared test, or Fisher’s exact test. Variables were tested for collinearity 
using Spearman correlations. 
A Kaplan-Meier survival curve was created for the overall arrhythmia-free survival time. 
In univariable analyses, each clinical, procedural and healthcare-related variable was 
assessed for crude (unadjusted) association with recurrence. Continuous variables 
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were analyzed as both continuous and as categorical (dichotomized at the median). 
Cox proportional hazard regression models were then created to identify statistically 
independent predictors of procedural failure. Modelling was not ‘data driven’ (e.g. 
stepwise) but was guided by clinical knowledge.  For example, likely confounders were 
identified and tested in models. These variables were determined from previous 
research, clinical experiences and face validity. All Cox proportional models tested were 
adjusted for age, sex, and type of AF regardless of significance level. Variables with p ≤ 
0.2 in univariable analyses were assessed in Cox proportional hazards models along 
with the identified confounders. The Cochran-Armitage trend test was used to test for an 
overall temporal trend with recurrence. Testing for temporal recurrence trends was a 
proxy to test the effect of operator experience. The level of statistical significance was 
set at 5 percent, two-tailed.   
Linearity was tested by adding quadratic terms. To test the proportional hazards 
assumption, lambdas were inspected visually and tested with time-dependent 
covariates. In the results, the estimated effects of variables on AF recurrence are 
presented as hazard ratios (HR) and 95% confidence intervals (CI).  
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Chapter 5  
5 Integrated Article: Predictors of arrhythmia recurrence 
following catheter ablation for AF 
Abstract 
Background 
Catheter ablation has emerged as more effective treatment for atrial fibrillation (AF) 
compared to anti-arrhythmic medications. Although the procedure continues to 
advance, recurrence of arrhythmias post-ablation remains high. Health care-related 
variables including wait time have not been explored as predictors of first ablation 
outcome. Wait times can be significant for non-urgent medical procedures in Canada. 
Objectives  
The primary objective was to identify patient, procedural, and health-care related factors 
associated with arrhythmia recurrences following catheter ablation for AF. The 
secondary objective was to compare baseline and procedural characteristics of patients 
with paroxysmal and persistent forms of AF. 
Methods 
314 consecutive patients with AF underwent first ablation for (83.4% paroxysmal AF, 
16.6% persistent AF). Follow-up visits occurred at 3, 6 and 12 months. Variables and 
the outcome of recurrence were modeled with Cox proportional hazards analysis. 
Results 
After a mean follow-up of 239+/-125 days, 110 patients (35.0%) experienced arrhythmia 
recurrence after single ablation. 
Adjusted Cox proportional hazards models demonstrated cardiomyopathy [HR (95% CI) 
= 1.97 (1.13-3.41)] was a predictor of arrhythmia recurrence. Conversely, height per cm 
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increase [HR (95% CI) = 0.96 (0.94-0.99)], and additional ablation targets [HR (95% CI) 
= 0.531 (0.29-0.98)] were associated with hazard reduction.  
Conclusions 
Clinical differences were observed in paroxysmal and persistent AF patients, though 
there was not a statistically significant difference in recurrence comparing these two 
groups. Cardiomyopathy and taller stature were predictive of recurrence. Targeted 
ablation outside the pulmonary veins when AF persisted beyond initial isolation was 
protective. Wait time for ablation was not associated with recurrence.  
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Predictors of arrhythmia recurrence after atrial fibrillation ablation 
5.1 Background 
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. 1-2% of the 
population is affected by AF, and the prevalence increases with age.1 In AF, chaotic 
electrical signals disrupt the normal conduction within the left atrium, resulting in 
irregular contractions of the cardiac chambers and potentially diminished cardiac output. 
AF increases the risk of stroke and is recognized as an independent predictor of 
morbidity and mortality in the setting of cardiovascular disease.2  
AF can be classified as either paroxysmal or persistent. Paroxysmal AF is defined as 
recurrent episodes of AF resolving within 7 days.3 Persistent AF is continuous AF 
lasting more than 7 days. However, the transient and often variable nature of AF poses 
limits to this categorization as patients can experience episodes of varying lengths. AF 
causes changes to the substrate of the atrium over time, creating an environment that 
favours AF.4 Over time paroxysmal AF episodes can become longer-lasting and more 
difficult to treat, which indicates progression to persistent AF.5  
The etiology of AF is incompletely understood. Triggers within the pulmonary veins have 
been implicated in the initiation and perpetuation of AF.6 Catheter ablation has emerged 
as a treatment modality for symptomatic patients who have not responded to anti-
arrhythmic medication.7,8 AF ablation aims to electrically isolate the foci within the 
pulmonary veins from the left atrium. Electrical isolation of the PVs from the rest of the 
left atrium prevents the triggers from initiating AF.9 
Catheter ablation aims to reduce the symptoms of AF by reducing or eliminating 
episodes and potentially changing sensory innervation which can reduce symptoms. 
Catheter ablation has not proven to reduce thromboembolic risk, whereas 
anticoagulation reduces the risk of stroke and is continued after ablation in patients who 
are at higher risk. Regardless of ambient risk, anticoagulation is prescribed for 1 month 
prior and 3 months after the ablation procedure to address the risk of clotting where 
ablation disrupts the integrity of the atrial surface. Though the procedure has been 
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refined over time, high recurrence rates following ablation remain a major challenge. 
Approximately 20-40% of patients experience arrhythmia recurrence after ablation.10,11 
PV reconnection, due to incomplete ablation, has been postulated by several studies to 
be the cause of early recurrences.12,13  Many studies have justified the use of a 
“blanking period” of 1-3 months where recurrences may occur but are not counted as 
recurrences in the study until they occur beyond the blanking period. However, there is 
evidence to suggest early recurrence frequently results in later recurrence, questioning 
the use of such blanking periods.14 
Identifying factors that contribute to the recurrence of arrhythmia is of clinical 
importance to reduce healthcare costs and avoid exposing patients to unnecessary 
procedures and related complications. Success rates have been lower in patients with 
persistent, compared to paroxysmal, AF even when a more aggressive ablation 
approach is used.15 This is likely due to the electro-anatomical changes that result from 
long term and continuous AF.   
Catheter ablation requires specialized skill and is performed in large health care 
centers.16 The length of time waited for catheter ablation in has not been explored when 
determining predictors of recurrence. Lengthy wait lists result in treatment delays, which 
is often the case for non-urgent procedures in a single payer health care system. 
Paroxysmal AF can progress to persistent AF, which may then require extensive 
ablation to block conduction.17 
Previous studies have identified many possible predictors of recurrence after ablation, 
though heterogeneous methodology and analyses have produced conflicting results. 
The primary objective of this study was to identify patient, procedural and health-care 
predictors of procedural failure following catheter ablation for AF. The secondary 
objective was to compare baseline and procedural characteristics of paroxysmal and 
persistent AF patients. 
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5.2 Methods 
This study was a retrospective cohort design using data from a prospectively collected 
atrial fibrillation clinical database by the Arrhythmia Service, London Health Sciences 
Centre. The database was initiated in 2009 and contains data on patient demographics, 
medical history, treatment, and follow up. Demographic and clinical data were collected 
at the time of first consult. Patients were routinely followed-up at approximately 3, 6 and 
12 months post-ablation. Patients were referred by family physician, internist or 
cardiologist from across Southwestern and Northern Ontario to London Health Sciences 
Centre, a regional referral centre for AF ablation. All patients provided both informed 
consent for the procedure and permission for their data to be used in research studies. 
This study was approved by Western University Ethics Board for Health Sciences 
Research.   
5.2.1 Study population 
All patients were included this study from the database who had either symptomatic 
paroxysmal or persistent AF, had failed to maintain sinus rhythm on at least one anti-
arrhythmic drug (AAD), and had not previously undergone an ablation for cardiac 
arrhythmia. Patients were not excluded on the basis of comorbid conditions, including 
those with underlying cardiovascular disorders or structural abnormalities (hypertension, 
coronary artery disease and cardiomyopathies). 
5.2.2 Procedure 
Prior to the procedure, all antiarrhythmic drugs were discontinued and patients received 
anticoagulation for 1 month prior and 3 months after ablation to reduce the risk of 
periprocedural thromboembolic events. Under general anesthetic or deep sedation, 
patients underwent standard pulmonary vein ablation. Catheters were introduced into 
the right atrium, right ventricle, and coronary sinus from the right femoral vein. 
Transseptal puncture was performed under fluoroscopy to obtain access to the left 
atrium. A circular mapping catheter and ablation catheter were then advanced to the left 
atrium. To reduce thermal risk to the adjacent esophagus, an esophageal temperature 
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probe was inserted. In most cases, a 3D anatomic map was created using an 
electroanatomical mapping system of the left atrium integrated with previously obtained 
CT images. Circumferential ablation lesions were made to encircle left and right 
pulmonary vein ostia in pairs. If AF did not terminate during pulmonary vein isolation, 
supplementary ablation lines were created as necessary. Specific additional ablation 
approaches included: mitral isthmus line (from the mitral annulus to the left inferior 
pulmonary vein), LA roof line (connecting the superior pulmonary veins across the 
superior posterior wall of the left atrium), and ablation of complex fractionated atrial 
electrograms (CFAEs), or a combination of these procedures. Electrical signals were 
observed during ablation for reduction in amplitude by at least 50% and lesions were at 
least 60 seconds in duration. All procedures took place between January 2009 and May 
2013. 
5.2.3 Follow up 
Patients were followed on an ambulatory basis in the arrhythmia service outpatient 
clinic. Patients underwent clinical examination at approximately 3, 6 and 12 months 
after the ablation procedure. Clinic visits included ECG, or 24-hour Holter monitor, 
symptom review, patient history and medication updates. 24-hour Holter monitors were 
used prior to 3- and 12-month visits. Event recorders were used prior to the 6 month 
clinic visit. Additional clinical visits were scheduled if indicated by symptoms.  
Arrhythmia-free survival time was measured in days from the procedure until recurrence 
was documented or until censoring occurred. Data were censored at the last known 
follow-up visit in the outpatient clinic or at 400 days (one year with one month of run-
out). 
5.2.4 Recurrence  
Recurrence was defined as at least one episode of documented arrhythmia (AF or 
atypical flutter) lasting more than 30 seconds at any time during follow-up. Atypical left 
atrial flutter was included in the recurrence definition. 
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A blanking period was not used in this study as there has been conflicting evidence for 
its validity. AF or atypical flutter at any time during follow up was recorded as procedural 
failure.  
5.2.5 Variables investigated  
5.2.5.1 Baseline sociodemographic and clinical data 
 
Sociodemographic and clinical variables investigated included: age (in years), sex, 
height (in cm) and weight (in kg). Body mass index (BMI) was calculated (in kg/m2) from 
baseline height and weight measurements. BMI is also expressed as a categorical 
variable according to the World Health Organization’s categorization (Normal: <25 
kg/m2, Overweight: 25–29.99 kg/m2, Obese ≥30 kg/m2).18 
Type of AF was categorized as paroxysmal (episodes resolved within 7 days) or 
persistent (episodes persisted beyond 7 days).3 Left atrial diameter (LAD) was 
measured (in mm) from echocardiography prior to ablation. CHADS2 scores were 
calculated for each patient (1 point each for Cardiac Failure, Hypertension, Age >= 75, 
Diabetes, 2 points for Stroke).19 Due to small numbers of patients with higher scores, 
this variable was dichotomized as ≤1 and ≥2.  
Patients were asked about their history of comorbid conditions including: hypertension, 
diabetes, prior stroke/transient ischemic attack (TIA), coronary disease, 
cardiomyopathy, depression, history of alcohol abuse, sleep apnea, and heart failure. 
Cardiomyopathy was defined as deterioration in the ability of the heart to contract. 
Although there are variants of cardiomyopathy, there was no distinction in type of 
cardiomyopathy in this study. Existing and previous health conditions were assigned as 
binary variables with yes or no responses. 
5.2.5.2 Procedure-related variables  
Procedural variables included: procedure duration (in minutes) and fluoroscopy duration 
(in minutes). If sinus rhythm was not achieved after pulmonary vein isolation, non-
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pulmonary vein triggers were identified and targeted for ablation. Specific targets 
include: LA roof line, CFAE, mitral isthmus line, tricuspid isthmus line. Cardioversion 
following the procedure was performed if patients remained in AF post-ablation. 
5.2.5.3 Healthcare-related variables 
Wait time (in months) was calculated as the number of months from the date the 
procedure was ordered to the scheduled procedure date.  
5.2.6 Statistical analysis 
All statistical analyses were performed in SAS v. 9.3. 
Continuous variables were expressed as mean ± SD and categorical variables were 
expressed as counts and percentages. To compare paroxysmal and persistent AF 
patients at baseline, Student’s t-test or Wilcoxon rank-sum test were used to analyze 
continuous variables, as appropriate. Categorical variables were analyzed using the chi-
squared test, or Fisher’s exact test. Variables were tested for collinearity using 
Spearman correlations. 
A Kaplan-Meier survival curve was created for the overall arrhythmia-free survival time. 
In univariable analyses, each clinical, procedural and healthcare-related variable was 
assessed for crude (unadjusted) association with recurrence. Continuous variables 
were analyzed as both continuous and as categorical (dichotomized at the median) in 
form. Cox proportional hazard regression models were then created to identify 
statistically independent predictors of procedural failure. Modelling was guided by 
clinical knowledge. Likely confounders were identified and tested in models. These 
variables were determined from previous research, clinical experiences and face 
validity. All Cox proportional models tested were adjusted for age, sex, and type of AF 
regardless of significance level. Variables with p ≤ 0.2 in univariable analyses were 
assessed in Cox proportional hazards models along with identified confounders. The 
Cochran-Armitage trend test was used to test for an overall trend over time with 
recurrence. Testing for temporal recurrence trends was a proxy to test the effect of 
operator experience. The level of statistical significance was set at 5 percent, two-tailed.   
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Linearity was tested by adding quadratic terms. To test the proportional hazards 
assumption, lambdas were inspected visually and tested with time-dependent 
covariates. In the results, the estimated effects of variables on AF recurrence are 
presented as hazard ratios (HR) and 95% confidence intervals (CI).  
5.3 Results 
5.3.1 Baseline clinical characteristics  
314 patients with AAD-refractory, symptomatic AF were included in this study. The 
mean patient age was 57.7+/-10.1 years, 27.1% were female, mean BMI was 29.7+/-
5.1. Hypertension was present in 149 patients (47.45%), 12.4% had heart failure, and 
10.8% had cardiomyopathy. Paroxysmal and persistent AF patients had similar baseline 
clinical and echocardiographic characteristics (Table 1), though persistent AF patients 
had a higher BMI (32.7+/-5.5 vs. 29.1+/-4.8, p < 0.0001), a larger left atrial diameter 
(47.5+/-5.8 vs. 41.2+/-5.5 mm, p < 0.0001), and more often had heart failure (28.9% vs. 
9.2%, p < 0.0001). 
5.3.2 Procedural and healthcare characteristics 
The mean duration of wait from time of booking to procedure date was 8.3+/-4.3 
months. The mean procedure duration was 231.2+/-59.3 minutes. Mean fluoroscopy 
duration was 21.8+/-12.5 minutes. Additional foci and atrial substrate modification were 
targeted for ablation in 76 patients (24.2%). These included LA roof line (16.0%), 
complex fractionated atrial electrograms (CFAEs) (11.8%), mitral isthmus line (3.2%), 
and the tricuspid isthmus line (20.4%). Ablation targets outside the PVs occurred more 
frequently in persistent compared to paroxysmal AF patients (78.9% vs. 13.4%, p < 
0.0001).  
5.3.3 Univariable analysis  
After a mean follow-up duration of 239.5 +/- 125.0 days, 110 patients (35.0%) 
experienced arrhythmia recurrence after single PVI (see Figure 1). On univariable 
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analysis, the hazard of recurrence was not statistically significant for persistent vs. 
paroxysmal AF patients [HR (95% CI) = 1.22 (0.76-1.97), p=0.03]. Mean time waited to 
procedure, in months, was not associated with recurrence [HR (95% CI) = 0.99 (0.95-
1.01), p=0.62]. Cardiomyopathy was the only variable associated with increased hazard 
of recurrence [HR (95% CI) = 1.77 (1.07-2.94), p=0.03]. Tests for temporal trends of 
recurrence by procedure year were not significant.  
5.3.4 Multivariable analysis  
The final Cox proportional hazards model included age, sex, type of AF, LA diameter, 
height, weight, cardiomyopathy, fluoroscopy duration and additional ablation targets 
(see Table 4). The multivariable analysis identified three variables as independent 
predictors of arrhythmia recurrence: height [HR per cm (95% CI) = 0.96 (0.94-0.99), p = 
0.01], presence of cardiomyopathy [HR (95% CI) = 1.97 (1.13-3.41), p = 0.02], and 
additional ablation targets [HR (95% CI) = 0.53 (0.29-0.98), p = 0.04].  
5.4 Discussion 
5.4.1 Principal study findings 
In the present study of 314 persistent and paroxysmal AF patients, cardiomyopathy, 
shorter height, and not requiring additional ablation to achieve sinus rhythm during the 
procedure were statistically independent predictors of recurrence. In the healthcare 
context, procedure wait time was not predictive of recurrence. The recurrence rate of 
persistent AF patients compared to paroxysmal AF patients did not reach statistical 
significance, though there were statistically significant differences in patient and 
procedural characteristics of these two groups. Comparing patients at baseline, a higher 
proportion of persistent compared to paroxysmal AF patients had AF risk factors 
including obesity and comorbid conditions.  
5.4.2 Cardiomyopathy 
Evidence regarding the efficacy of ablation for AF in cardiomyopathy patients is limited, 
and often it is an exclusion criterion in clinical trials. In a small study of 61 patients with 
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hypertrophic cardiomyopathy and AF, Di Donna and colleagues20 found that 72% of 
patients who underwent catheter ablation experienced recurrence after a single 
procedure. High rates of recurrence were also observed by Santangeli et al21 in a study 
of 43 AF patients with hypertrophic cardiomyopathy. After one procedure, 47% of 
patients had arrhythmia recurrence within one year. After long term follow-up of a 
median of 42 months, 51% of patients remained in AF, even after repeat procedures.  
In the current study, 34 (10.8%) AF patients had cardiomyopathy, with a higher 
proportion observed among persistent compared to paroxysmal AF patients (17.3% vs. 
9.5%), though statistical significance was not reached. Cardiomyopathy increased the 
hazard of recurrence and remained a statistically significant predictor of recurrence after 
adjustment in the multivariable model. The definition of cardiomyopathy in this study 
was broad and included different types. Although severity of disease may be different 
across patients due to the inclusive definition, the increased hazard of recurrence aligns 
with previous studies. 
5.4.3 Height 
Height has been implicated in incident AF. In a large cohort study of older US adults, 
Rosenberg and colleagues22 found that independent of sex, increased height was 
significantly associated with the risk of incident AF. There is evidence to suggest tall 
stature may be associated with the initial development of AF, though the results from 
the current study suggest that recurrent AF is associated with shorter height. Increased 
height (per centimeter) was associated with a small reduction in hazard of arrhythmia 
recurrence after catheter ablation for AF.  
5.4.4 Non-pulmonary vein ablation targets 
Isolation of the pulmonary veins is the cornerstone of treatment in both paroxysmal and 
persistent patients. However, targeting additional ablation foci has not been consistently 
associated with reduced recurrence.15,23 In the STAR AF II trial23, persistent AF patients 
were assigned to one of three procedure variants: pulmonary vein isolation alone, or 
pulmonary vein isolation with the addition of either isolation of complex fractionated 
atrial electrograms or linear ablation across the left atrial roof and mitral valve isthmus. 
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No reduction in the rate of recurrent AF was detected when additional ablation areas 
were created in conjunction with pulmonary vein isolation.  
In the current study, additional targets for ablation were guided by the persistence of AF 
after pulmonary vein isolation and not limited to a specific subset of patients. 24.2% of 
patients required additional targeted ablation to achieve sinus rhythm. Among these 
patients, 35/76 had paroxysmal AF (13.4% of paroxysmal patients) and 41/76 were 
persistent AF (78.9% of all patients with persistent AF) patients (p<0.0001). However, 
the addition of targeted ablation lesions was associated with nearly a 50% decrease in 
the hazard of recurrence [HR (95% CI) = 0.53 (0.29-0.98)]. Recurrence rates in 
paroxysmal patients compared to persistent patients did not reach statistical 
significance. 
5.4.5 Procedure wait time 
In the Canadian context, the absence of association with procedure wait time and 
recurrence of arrhythmia after catheter ablation suggests that even though patients 
waited a mean of 8.3 months, there was not enough evidence to suggest they are at 
increased risk of recurrence. As the population ages and more Canadians are affected 
by AF, wait times are likely to increase. It is relevant to understand this relationship to 
plan healthcare resources appropriately.  
5.4.6 Limitations 
Arrhythmia recurrence may have been underestimated in this study. Patients were not 
monitored continuously and therefore asymptomatic or nocturnal episodes may have 
been undetected. It is unlikely that short, asymptomatic episodes would be recorded at 
the regularly scheduled clinic visits. Event recorders were used prior to scheduled visits 
for each patient to collect more comprehensive data and minimize ascertainment bias. It 
is possible that events requiring patients to seek emergency medical attention were not 
captured, as data were not collected from outside departments or facilities. Therefore, 
the actual recurrence rate including minor episodes is almost certainly higher than 
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reported. However, the clinical significance of minor or asymptomatic episodes, and the 
bias posed by their omission, is unclear.  
The technique for ablation was not uniform across all patients in the study population. 
All patients underwent PV isolation, though additional ablation areas were targeted at 
the discretion of the treating physician if sinus rhythm was not achieved through PV 
isolation alone.  
This study is also limited by its observational nature. It was non-randomized and from a 
single center with a group of expert operators. Patients who were ultimately ablated and 
included in this study were chosen for the procedure by a physician. The number of 
patients excluded prior to ablation is uncertain. 
Additional outcome measures, such as quality of life and AF-specific symptom 
assessment, would have provided more information about relevant outcomes after 
ablation. Ablation aims to reduce symptoms by eliminating AF altogether, though 
documented arrhythmia recurrences do not provide information on symptoms. Patients 
with documented arrhythmia post-ablation may still have an improved quality of life from 
a reduction of symptoms. Time to recurrence is just one method for evaluating 
procedural failure. Arrhythmia burden, or the frequency and severity of symptoms, may 
be an important factor to patients, though more difficult to assess clinically. 
It is important to note that this study did not use a blanking period as some studies have 
previously. Several studies have found associations between early recurrences and 
later recurrences24 and it is hypothesized that early recurrences are a result of 
incomplete ablation and thus should be counted as such.25,26 
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Table 1: Baseline clinical characteristics of AF patients presenting for initial 
ablation 
  All 
Paroxysmal 
AF 
Persistent 
AF P value* 
  (n=314) (n=262) (n=52)  
Age, years 57.7 (10.1) 57.9 (10.3) 57.0 (8.7) 0.57 
Sex, female 85 (27.1%) 75 (28.6%) 10 (19.2%) 0.16 
Weight, kg 92.0 (17.9) 89.7 (16.6) 103.8 (19.7) <0.0001 
Height, cm 176.0 (10.0) 175.6 (10.1) 178.0 (9.2) 0.11 
BMI, kg/m2 29.7 (5.1) 29.1+/-4.8 32.7 (5.5) <0.0001 
BMI category    <0.0001 
Normal weight   54 (17.2%) 49 (18.7%) 5 (9.62%)  
Overweight 129 (41.1%) 118 (45.0%) 11 (21.2%)  
Obese 131 (41.7%) 95 (36.3%) 36 (69.2%)  
LA diameter, mm 42.3 (6.0) 41.2 (5.5) 47.5 (5.8) <0.0001 
CHADS2 score, 
dichotomized    0.52 
0 or 1 246 (78.3%) 207 (79.0%) 39 (75.0%)  
More than 1 68 (21.7%) 55 (21.0%) 13 (25.0%)  
Comorbid 
conditions     
Hypertension 149 (47.45%) 121 (46.2%) 28 (53.85%) 0.31 
Diabetes 31 (9.9%) 23 (8.8%) 8 (15.4%) 0.14 
Prior stroke/TIA 32 (10.2%) 29 (11.1%) 3 (5.8%) 0.25 
Coronary disease 17 (5.4%) 12 (4.6%) 5 (9.6%) 0.14 
Cardiomyopathy 34 (10.8%) 25 (9.5%) 9 (17.3%) 0.10 
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Depression  10 (3.2%) 8 (3.1%) 2 (3.9%) 0.77 
History of alcohol 
use 17 (5.4%) 13 (5.0%) 4 (7.7%) 0.43 
Sleep apnea 39 (12.4%) 29 (11.1%) 10 (19.2%) 0.10 
Heart failure 39 (12.4%) 24 (9.2%) 15 (28.9%) <0.0001 
Data expressed as mean (SD) or count (%) of patients 
*P≤0.05 considered statistically significant  
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Table 2 - Procedural characteristics of initial ablation procedure in paroxysmal and 
persistent AF patients 
  All 
Paroxysmal 
AF 
Persistent 
AF P value* 
  (n=314) (n=262) (n=52)   
Procedure duration, min 
231.2 
(59.3) 224.5 (55.5) 264.6 (66.8) <0.0001 
Fluoroscopy duration, 
min 21.8 (12.5) 21.2 (12.7) 24.5 (11.4) 0.09 
Additional targets 
ablated 76 (24.2%) 35 (13.4%) 41 (78.9%) <0.0001 
LA roof line 50 (16.0%) 25 (9.5%) 25 (48.1%) <0.0001 
CFAE 37 (11.8%) 14 (5.3%) 23 (44.2%) <0.0001 
Mitral isthmus line 10 (3.2%) 4 (1.5%) 6 (11.4%) 0.002 
Tricuspid isthmus line 64 (20.4%) 53 (20.2%) 11 (21.2%) 0.88 
Cardioversion required 
post-ablation 18 (5.7%) 8 (3.1%) 10 (19.2%) <0.0001 
Wait time, months 8.3 (4.3) 8.4 (4.4) 7.7 (3.6) 0.28 
Data expressed as mean (SD) or count (%) of patients 
*P≤0.05 considered statistically significant  
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Figure 1 Kaplan-Meier survival curve: Freedom from recurrence after initial AF catheter 
ablation 
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Table 3. Univariable analysis of clinical, procedural and healthcare-related variables 
and their association with recurrence 
  HR (95% CI) P value 
     
Age, years 1.00 (0.98-1.01) 0.65 
age > median 0.92 (0.63-1.34) 0.67 
Sex, female 1.12 (0.73-1.70) 0.61 
Persistent AF 1.22 (0.76-1.97) 0.41 
Weight, kg 1.00 (0.99-1.01) 0.59 
weight > median 1.05 (0.72-1.53) 0.80 
Height, cm 0.99 (0.97-1.00) 0.11 
height > median 0.69 (0.46-1.02) 0.06 
BMI, kg/m2 1.03 (0.99-1.07) 0.11 
BMI>median 1.15 (0.79-1.68) 0.46 
BMI category   
Normal weight   1.0 (reference) -- 
Overweight 1.35 (0.75-2.42) 0.31 
Obese 1.63 (0.91-2.90) 0.10 
LA diameter, mm 1.02 (0.98-1.05) 0.33 
LA diameter>median 1.00 (0.69-1.45) 1.00 
CHADS2 score 1.26 (0.82-1.95) 0.29 
Comorbid conditions   
Hypertension 1.03 (0.71-1.50) 0.88 
Diabetes 1.26 (0.69-2.30) 0.45 
Prior stroke/TIA 0.97 (0.52-1.81) 0.92 
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Coronary disease 1.10 (0.48-2.50) 0.83 
Cardiomyopathy 1.77 (1.07-2.94) 0.03 
Depression  1.24 (0.46-3.38) 0.67 
History of alcohol abuse 1.66 (0.84-3.28) 0.15 
History of smoking 1.28 (0.84-1.94) 0.26 
Sleep apnea 1.28 (0.74-2.21) 0.38 
Heart failure 0.99 (0.56-1.77) 0.98 
Procedure duration, min 1.00 (1.00-1.00) 0.51 
Duration>median 1.23 (0.85-1.80) 0.27 
Fluoroscopy duration, 
min 1.02 (1.00-1.03) 0.02 
Fluoroscopy time>median 1.27 (0.87-1.86) 0.21 
Additional targets 
ablated 0.89 (0.56-1.40) 0.60 
LA roof line 0.82 (0.47-1.43) 0.47 
CFAE 0.82 (0.44-1.54) 0.54 
Mitral isthmus line 0.97 (0.36-2.63) 0.95 
Tricuspid isthmus line 1.37 (0.90-2.10) 0.14 
Cardioversion required 
post-ablation 1.51 (0.70-3.25) 0.29 
Wait time, months 0.99 (0.95-1.03) 0.62 
months waiting > median 0.86 (0.59-1.25) 0.43 
HR= Hazard ratio 
 
 
59 
 
Table 4. Adjusted Hazard Ratios (HR) from multivariable Cox proportional hazards 
model 
  HR (95% CI) P value 
Age, years 0.99 (0.97-1.01) 0.49 
Sex, female 0.76 (0.41-1.42) 0.39 
Persistent AF, present 1.44 (0.76-2.70) 0.26 
LA diameter, mm 1.02 (0.98-1.05) 0.43 
Height, cm 0.96 (0.94-0.99) 0.01 
Weight, kg 1.00 (0.99-1.02) 0.55 
Cardiomyopathy, present 1.97 (1.13-3.41) 0.02 
Fluoroscopy duration, min 1.02 (1.00-1.03) 0.01 
Additional ablation areas targeted to 
achieve sinus rhythm, yes 0.53 (0.29-0.98) 0.04 
HR= Hazard ratio 
  
60 
 
Chapter 6 
6 Discussion 
The current study included 314 patients with drug-refractory paroxysmal or persistent 
AF who underwent first catheter ablation. Clinical, procedural, and health care –related 
factors were evaluated to assess their association with arrhythmia recurrences following 
ablation. Cardiomyopathy and shorter stature were predictive of recurrence. Targeted 
ablation of areas outside the pulmonary veins when AF persisted beyond the isolation of 
the pulmonary veins was a protective factor. There was not enough evidence to suggest 
a difference in the recurrence rate of paroxysmal compared to persistent AF patients. 
Wait time for the procedure was not associated with recurrence. 
6.1 Cardiomyopathy 
Cardiomyopathy presents a challenge for the long term success of catheter ablation for 
AF, as observed in this study. Cardiomyopathy was an independent predictor of 
recurrence. This is complicated by the fact that AF is much more common in patients 
with hypertrophic cardiomyopathy compared to the general population (25% vs. 1-2%).1 
In the current study, 34/314 (10.8%) patients had cardiomyopathy. A higher proportion 
of persistent patients had concurrent cardiomyopathy (17.3%) in comparison with 
paroxysmal AF (9.5%), though it did not reach statistical significance. The definition of 
cardiomyopathy in the current study was inclusive to different types of 
cardiomyopathies, though variations have similar symptoms and all affect the ability of 
the heart muscle to contract. However, variation in disease severity may exist. 
Evidence regarding the efficacy of ablation for AF in cardiomyopathy patients is limited, 
as comorbid conditions are often excluded from clinical trials. In this study, AF patients 
with cardiomyopathy had increased hazard of recurrence and remained a statistically 
significant predictor of recurrence after adjustment in the multivariable model. A 
multicenter study consisting solely of cardiomyopathy patients with AF, Di Donna and 
colleagues found that 44 of 61 patients (72%) experienced recurrence after the first 
procedure.2 After a subsequent ablation in 32 patients, the overall recurrence rate was 
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33%. In that study, multivariable Cox regression models indicated the independent 
predictors of AF recurrence were increased left atrial volume and New York Heart 
Association (NYHA) functional class, which classifies heart failure according to 
symptom severity. The current study did not include NYHA functional class, though it 
may have provided additional information about the severity of cardiomyopathies among 
AF patients. 
Santangeli et al3 also observed high rates of recurrence among patients with 
cardiomyopathies. In a small study of 43 AF patients with hypertrophic cardiomyopathy, 
47% of patients had arrhythmia recurrence within one year after a single procedure. AF 
triggers outside the pulmonary veins were identified in all patients and were responsible 
for late recurrences during subsequent re-ablation. In the present study, AF triggers 
outside the pulmonary veins were identified and ablated when AF continued after the 
initial isolation of the pulmonary veins. Though after adjusting for cardiomyopathies, 
additional ablation reduced the hazard of recurrence in the current study. 
6.2 Body size 
The results of this study suggest increased height (per centimeter) was associated with 
reduced hazard of recurrence after catheter ablation. Height was consistently 
associated with recurrence, even after adjustment.  
Height has been implicated in the development of AF, though taller stature has been 
associated with the initial development of AF. Rosenberg and colleagues4 found that 
after adjustment for sex, increased height was significantly associated with the risk of 
incident AF. In modeling the risk of AF development, they found that the higher risk 
among males was completely attenuated for by the inclusion of height. However, no 
such relationship has been observed between height and recurrence of AF in patients 
who have undergone catheter ablation.   
A significant proportion of patients in this study were overweight and obese. Indeed, 
82.8% of the patients in this study were overweight or obese, according to the WHO 
defined body mass index categories.5 The mean BMI of patients in this study was 29.7 
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kg/m2, which is nearly obese. Overweight and obese categories of BMI each had an 
increase in hazard of recurrence compared to the normal BMI category, though 
statistical significance was not reached. Therefore, there was not enough evidence to 
suggest BMI was associated with arrhythmia recurrences following catheter ablation in 
the current study. A larger sample size may have yielded significant results. The 
elevated BMIs found in AF patients in this study are similar to those observed in 
population-based studies of incident AF.6  
Tedrow and colleagues7 observed a large cohort of women and found that the risk of 
incident AF was linearly associated with increasing BMI. Among women who became 
obese during the study period, there was a 41% increase in AF development, compared 
to non-obese women. The risk of AF among those who became obese exceeded that of 
the women who were obese at baseline and remained obese. Importantly, those who 
were obese and decreased their BMI below 30 did not differ from the risk of non-obese 
women at baseline who remained non-obese. This study suggests a reversibility of 
obesity-associated AF risk increase. Rosengren et al8 came to the same conclusion in a 
cohort of males. Risk factor reduction plays an important role in mitigating the 
development of AF, though little is known about whether it plays a role in reducing AF 
recurrence.  
To understand the impact of risk factor reduction on AF patients who had undergone 
catheter ablation, Pathak and colleagues9 compared AF patients enrolled in a clinical 
risk factor management therapy program and those who were given information on risk 
factor management. Management was aimed at aggressively treating and managing 
blood pressure, weight, cholesterol, blood sugar for diabetics, sleep apnea, smoking, 
and excessive alcohol use. Patients enrolled in risk factor management therapy 
experienced better long term outcomes after catheter ablation on both first procedure 
and last procedure they underwent for catheter ablation. Reductions in left atrial 
volumes were observed in both groups. They concluded that the modification of risk 
factors that promote atrial substrate changes associated with AF can help maintain 
sinus rhythm post-ablation. However, the study aggressively aimed to reduce all risk 
factors at once, so it does not provide insight to the relative contribution of each 
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individually. It does provide evidence to suggest AF patients may achieve better 
outcomes through positive lifestyle changes. Similarly, a recent study observed that 
weight reduction and risk factor management in overweight individuals with AF resulted 
in a reduction of the AF symptom burden.10 Body mass was not measured over time in 
this study and it is not known whether changes in body mass may have an effect on 
recurrence after cathether ablation for AF. 
6.3 Non-pulmonary vein ablation targets 
While pulmonary vein isolation is the cornerstone of treatment in both paroxysmal and 
persistent patients, targeting additional foci outside the pulmonary veins has not been 
consistently associated with reduced recurrence.11, 12 Verma et al did not find a benefit 
associated with performing additional ablation lesions in persistent AF patients.13 In that 
study, patients were randomly assigned to receive either pulmonary vein isolation alone 
or combined with ablation of CFAEs or linear ablation of the left atrial roof and mitral 
valve isthmus.  
The present study targeted the same areas for ablation as the study by Verma et al13 
though only when arrhythmia persisted after standard pulmonary vein isolation. The 
addition of targeted ablation lesions to select patients was associated with nearly a 50% 
decrease in hazard of recurrence [HR (95% CI) = 0.53 (0.29-0.98)]. This finding is 
similar to that of on-treatment analysis of the CONFIRM trial, which suggested fewer AF 
recurrences when all ectopic sources are eliminated, with a graded increase in 
recurrence of arrhythmia with more sources missed.14 Likewise, Gaita and colleagues, 
found that the addition of linear ablation lesions resulted in a lower recurrence rate in 
both paroxysmal and persistent AF patients compared to pulmonary vein isolation 
alone.15  
Clinically relevant conclusions may be drawn about the optimal ablation strategy in 
these patients. Ablation in addition to the pulmonary veins was associated with a 
statistically significant arrhythmia-free survival benefit in the current study. However, 
assigning patients to receive additional ablation without evidence to suggest conduction 
64 
 
outside the pulmonary veins may not be an ideal ablation strategy. More extensive 
ablation can cause scarring and may be pro-arrhythmic. Indeed, areas of incomplete 
ablation or where conduction block has not been achieved may promote arrhythmia 
recurrence.16 
6.4 Type of atrial fibrillation 
Most published studies of catheter ablation have involved patients with paroxysmal AF. 
Small studies of persistent AF have reported higher recurrence rates than those in 
studies of paroxysmal AF.17, 18 Catheter ablation in patients with persistent AF remains 
controversial. Although there were differences in paroxysmal and persistent AF patients 
at baseline, there was no evidence of a statistically significant difference in hazard of 
recurrence in persistent compared to paroxysmal AF in crude or adjusted models 
examined. While a large variety of approaches to PVI exist for persistent AF patients, 
recurrence rates have varied drastically from as low as 9% to 92%.19, 20  
6.5 Wait time 
To the best of our knowledge, this is the first study we are aware of that examined 
waiting time as a predictor of recurrence in catheter ablation for AF. In the Canadian 
context, the absence of association with procedural wait time and recurrence of 
arrhythmia after catheter ablation suggests that even though patients are waiting a 
mean duration of 8.3 months, 5 months longer than the recommended Canadian target 
for ablation procedures, they are not at increased risk of recurrence. As the population 
ages and more Canadians are affected by AF, wait times are likely to increase. It is 
relevant to gain insight on this relationship to plan healthcare resources appropriately.  
The measure included in this study only included the duration of time from the 
scheduling date to the ablation date. It does not account for the duration of time waited 
prior to the decision to ablate, which may be highly variable.21 Knudtson et al22 have 
proposed that it is likely that patients face the greatest wait-related risk in the earlier 
phases of care, before the disease is adequately characterized. The complex pathway 
to ablation includes several individual time intervals, including access to primary care, 
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access to specialist consultation, the decision to treat (including wait time for diagnostic 
tests and subsequent consultations), and finally, the wait time to ablation. I this study, 
only the final interval was included for analysis. By measuring different wait times, it 
may be possible to examine where in the healthcare pathway the wait times are 
unacceptable or may be contributing to inferior patient outcomes. 
6.6 Impact of definitions 
6.6.1 Recurrence 
The definition of recurrence is heterogeneous in the existing literature. It is possible that 
the definition of outcome impacted the results of the study. A “blanking” period of 1-3 
months following ablation is sometimes used in studies, which allows patients to 
experience recurrence without identifying them as procedural failures. However several 
studies have found associations between early recurrences and later recurrences.23 It is 
hypothesized that early recurrences are a result of incomplete ablation and subsequent 
re-conduction.24, 25 Therefore, allowing blanking periods may underestimate the true 
recurrence rate. Documented AF or atypical flutter any time post-ablation was 
considered recurrence of arrhythmia in this study. A blanking period was not used. 
Including only AF recurrence, instead of atypical flutter and AF, a lower overall 
recurrence rate would have been reported. Different results in the literature may be 
partially attributable to the definitions used in each particular study. Definitions may be 
further complicated by not counting recurrences if sinus rhythm could be maintained on 
anti-arrythmia medications following ablation. 
6.6.2 Type of atrial fibrillation 
Although there is agreement in the general definitions of paroxysmal and persistent AF, 
there are variations in how it can be clinically defined. Paroxysmal AF consists of 
recurrent episodes of AF resolving within 7 days, while persistent AF is continuous 
beyond 7 days.26 However, the transient and often variable nature of AF poses limits to 
this categorization as patients can experience episodes of varying lengths. Additionally, 
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AF causes changes to the substrate of the atrium over time, creating an environment 
that favours AF.27, 28 Paroxysmal AF can progress to persistent AF and may not be 
captured in observational or retrospective studies of clinical records. Differences in 
studies may be partly due to the somewhat subjective categorization of AF type. 
Without continuous monitoring, AF classification is based on clinical evaluations, 
patients’ symptoms and short-term monitoring.   
6.7 Limitations 
This study included a relatively large number of patients, though some baseline 
characteristics had small counts. Ablation is constantly evolving, and although this 
center experienced no major changes in ablation equipment, the procedure itself is 
constantly being refined.   
Arrhythmia recurrence may have been underestimated in this study. Patients were not 
continually monitored and asymptomatic recurrences may not be recorded at regularly 
scheduled clinic visits. Therefore, the actual recurrence rate may be higher than 
reported due to imperfect monitoring. 24-hour Holter, or loop event recorders were used 
to assess the rhythm status of patients at each follow-up visit. Events that occurred 
outside monitoring in a different facility or in an emergency room setting would not be 
captured. Data was not collected outside the department. Only documented arrhythmia 
events were included as failures. More aggressive monitoring may have captured more 
recurrences, but in the absence of symptoms, there is little evidence that these events 
are clinically significant. 
This study is also limited by its observational nature. It was non-randomized and from a 
single center with a group of expert operators. Patients who were ultimately ablated and 
included in this study were chosen for the procedure by a physician. The number of 
patients excluded prior to ablation is uncertain, as is the reason. 
Additional measures of outcomes, such as quality of life, arrhythmia burden, and AF-
specific symptom assessment, would have provided more information about relevant 
outcomes after ablation. Documented arrhythmia recurrences do not provide 
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information on symptoms. Even patients with documented arrhythmia post-ablation may 
have an improved quality of life from a reduction of symptoms. 
  
6.8 Clinical Implications 
An optimal strategy for the ablation of AF has yet to be established. This study provides 
additional evidence in support of a tailored approach for catheter ablation. All patients 
underwent PVI, though additional triggers were identified and ablated if sinus rhythm 
was not achieved after PVI alone. However, because not every patient underwent the 
same procedure, the individualized nature of the procedure itself may have affected the 
results of this study, though the results are comparable to previous studies. 
Bottoni and colleagues29 recently published the results from a multicenter study of 218 
patients who had failed one or more attempts at catheter ablation for either paroxysmal 
or persistent AF over a ten year period. Although the ablation strategy changed over the 
study period, the results suggest that after failed catheter ablation and the subsequent 
initiation of other antiarrhythmic therapies, only 15% of patients reported worse 
outcomes compared to their pre-ablation period. A drawback to this study is that pre-
ablation status was self-reported and subject to recall bias as the mean time since 
ablation was 5 years. However, it is still indicative that patients had a positive outlook 
after ablation for AF. Similarly, Wokhlu et al30 found quality of life improvements at 2 
years post-ablation in patients with and without recurrence.  
Because of the high recurrence rates still observed in AF patients following ablation, it is 
important to balance patient characteristics, symptoms and risks of ablation. 
Stratification by factors may help with patient selection for the procedure and to inform 
the risk-benefit ratio. 
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